Biomarker Strategic Planning and Literature Review

Jul 18, 2017 | Biomarkers, News

We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various...

Biomarkers and The Adoption Cycle: Where are we now?

Oct 31, 2016 | Biomarkers, News

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use...

Chart of the Week: Update: Unique Biomarkers in Pharma

May 24, 2016 | News

On January 29th, we posted a CotW outlining the top 10 pharma companies by number of unique biomarkers those companies are using in trials.  We thought it was about time to update that chart and expand it to the top 25 pharma companies. Interesting facts to note:...

Precision Medicine Innovation Not Just a Numbers Game

May 11, 2016 | News

We published a revision to our Precision Medicine Scorecard: Drug Company Edition last month. As John Audette rightfully notes, there are multiple factors in a pharmaceutical company’s contribution to precision medicines: How many precision medicines a company...

Biomarker Panels Explode in LDTs

May 4, 2016 | News

In this blog we have regularly assumed (without hard data until now) that most biomarker innovation was taking place in laboratory-developed tests (LDTs) as opposed to tests cleared and approved by FDA, and we can now confirm that this assumption is correct. Now that...